Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

BACKGROUND: In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, patients received KRd for a maximum of 18 cycles fo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Hematol Oncol
Главные авторы: Dimopoulos, Meletios, Wang, Michael, Maisnar, Vladimir, Minarik, Jiri, Bensinger, William, Mateos, Maria-Victoria, Obreja, Mihaela, Blaedel, Julie, Moreau, Philippe
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2018
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5883881/
https://ncbi.nlm.nih.gov/pubmed/29615082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0583-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы